Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project

Walker, Lisa A.S.; Osman, Leila; Berard, Jason A.; Rees, Laura; Freedman, Mark S.; MacLean, Heather; Cousineau, Denis

doi:10.1016/j.jns.2016.01.040

Cited by 60 publications

(48 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The battery comprises the Symbol Digit Modalities Test, California Verbal Learning Test -II (first five recall trials), and Brief Visuospatial Memory Test -Revised (first three recall trials). However, even though its validation is currently under development in different languages and countries, the process has been completed only in a few countries (Dusankova, Kalincik, Havrdova, & Benedict, 2012;Eshaghi et al, 2012;Giedraitienė, Kizlaitienė, & Kaubrys, 2015;Goretti et al, 2014;O'Connell, Langdon, Tubridy, Hutchinson, & McGuigan, 2015;Sandi et al, 2015;Spedo et al, 2015;Walker et al, 2016) and therefore is not yet worldwide available for use in clinical practice. Furthermore, some instruments have been recommended for the screening of CD in MS patients, namely the Symbol Digit Modalities Test (SDMT; Rao, 1991;Smith, 1982), with reported high sensitivity (.91) but poor specificity (.60) (Van Schependom et al, 2014) and good reliability in monitoring cognitive function over time (Morrow et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis

Freitas

Batista

Afonso

et al. 2016

Applied Neuropsychology: Adult

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis

Freitas

Batista

Afonso

et al. 2016

Applied Neuropsychology: Adult

View full text Add to dashboard Cite

show abstract

“…Barriers lengthen the time that mental health concerns go untreated, which is associated with a negative prognosis. 39 Validated screening tools should be adopted to better identify cognitive 9,42 and mental health concerns. 22,23 The low identification rate may be because clinicians elect not to assess concerns, as has been reported anecdotally by clinic staff.…”

Section: Discussionmentioning

confidence: 99%

“…The Brief International Cognitive Assessment for MS (BICAMS) can be administered by nonspecialized staff. [8][9][10][11][12][13] Despite this, cognitive issues are not adequately addressed, as traditional neurologic practice dominates over interdisciplinary approaches. 2,7,14 Up to 50% of people with MS experience depression.…”

Section: Methodsmentioning

confidence: 99%

Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center

Walker¹,

Gardner²,

Freedman³

et al. 2019

International Journal of MS Care

Self Cite

View full text Add to dashboard Cite

Background: People with multiple sclerosis (MS) are at increased risk for cognitive impairment, mental health concerns, and psychosocial issues, which can negatively affect disease outcomes and quality of life. Current MS care guidelines recommend integrated interdisciplinary services to address these concerns; however, issues can be overlooked during routine care. To date, there is inadequate research on how often these issues are identified and addressed during routine MS care. Methods: One hundred medical records were randomly selected and reviewed (55 relapsing-remitting MS, 17 secondary progressive MS, 8 primary progressive MS, and 20 other or subtype not indicated). All visits to, and contacts with (ie, telephone, e-mail), an MS clinic over 1 year were included in the analysis to determine the proportion of patients presenting with cognitive, mental health, and psychosocial concerns and the proportion of patients offered associated services. Results: Of the 25 patients with at least one identified concern, treatment recommendations occurred for 13 (52%). Rates of identification of cognitive, mental health, and psychosocial concerns in standard clinical practice were significantly lower than the identified prevalence in epidemiologic studies. Demographic factors had no bearing on who was offered treatment. Patients with concerns access MS clinic services more often than those without. Conclusions: Discrepancies between reported and expected frequencies may be due to overreliance on patient self-disclosure and concerns by the health care team that inadequate resources are available to address issues. An interdisciplinary team model may help address these issues.

show abstract

“… 49 It includes three tests of high reliability and sensitivity: Rao’s adaptation 10 of the SDMT, 50 the initial learning trials of the CVLT II 51 and the BVMT-R. 52 International validations are currently underway and up to now normative data exist for a number of countries. 53 – 57 Fortunately, as per LATAM, Spedo et al. 58 and Vanotti et al.…”

Section: Cognitive Assessmentmentioning

confidence: 98%

Cognitive and neuropsychiatric disorders among MS patients from Latin America

Vanotti¹,

Cáceres

2017

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Cognitive and neuropsychiatric disorders in patients with multiple sclerosis have been extensively documented. The focus of this review will be on cognitive and neuropsychiatric disorders in multiple sclerosis patients from Latin America, in the context of international literature. Multicentre studies carried out in Latin America have shown that 43% of the patients have cognitive impairment and 34.5% in early stages of the disease, 29% depression and 20.9% neuropsychiatric disorders. The profile of cognitive impairment corresponds to alterations in visual and verbal memory, in attention, in information processing speed and in verbal fluency. The neuropsychiatric profile showed disorders in anxiety, depression, apathy and irritability domains. In the region, there exist validations of the multiple sclerosis neuropsychological screening questionnaire (MSNQ), the brief repeatable battery of neuropsychological tests (BRB-N) and the brief international cognitive assessment for multiple sclerosis (BICAMS), as well as of the paced auditory serial addition test (PASAT) and the symbol digit modalities test (SDMT). A study showed that 53% of the patients who met the NEDA3 condition had cognitive impairment. This finding highlights the need for taking cognitive assessment into account when determining therapeutic efficacy.

show abstract

Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project

Cited by 60 publications

References 42 publications

The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis

The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis

Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center

Cognitive and neuropsychiatric disorders among MS patients from Latin America

Contact Info

Product

Resources

About